Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

Texas MPN Workshop 2022 | BET inhibition as a novel targeted therapy for myelofibrosis

Lucia Masarova • 26 Aug 2022

Texas MPN Workshop 2022

Myelofibrosis Myeloproliferative Neoplasms Pelabresib Ruxolitinib

COMFORT-I COMFORT-II MANIFEST MANIFEST-2

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promise of BET inhibition as a novel targeted therapy in patients with myelofibrosis (MF). Dr Masarova first highlights some findings from the MANIFEST trial (NCT02158858), evaluating the safety and efficacy of pelabresib, a BET inhibitor, in combination with ruxolitinib in patients with MF. Dr Masarova then discusses the ongoing MANIFEST-2 trial (NCT04603495), and concludes by highlighting various ways of incorporating pelabresib in MF treatment. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

What's on the horizon for the treatment of MPNs?

Lucia Masarova • 9 Dec 2023

Splicing mutations in post-ET/post-PV myelofibrosis

Lucia Masarova • 9 Dec 2023

Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1

Lucia Masarova • 9 Dec 2023

Cladribine-based chemotherapy for patients with secondary AML arising after MPNs

Lucia Masarova • 9 Dec 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023